Home

  • Order to parcel locker

    Order to parcel locker

  • easy pay

    easy pay
  • Reduced price
Preventive Pharmacotherapy of Headache Disorders

Preventive Pharmacotherapy of Headache Disorders

9780198528449
1,737.45 zł
1,563.70 zł Save 173.75 zł Tax included
Lowest price within 30 days before promotion: 1,563.70 zł
Quantity
Available in 4-6 weeks

  Delivery policy

Choose Paczkomat Inpost, Orlen Paczka, DPD or Poczta Polska. Click for more details

  Security policy

Pay with a quick bank transfer, payment card or cash on delivery. Click for more details

  Return policy

If you are a consumer, you can return the goods within 14 days. Click for more details

Description
Most of the familiar headache drugs are used to stop a headache attack that is already in progress, or about to begin. However, there is now a growing body of research aimed at developing medications that can be taken on a regular basis to prevent headcahes from starting. These drugs will be targetted at patients whose headaches are frequent or who get their headaches at predicatble times. This book reviews the potential for prophylactic treatment of headache. It provides most ofthe existing evidence in the field of pharmaco-prophylaxis of migraine and other chronic headaches and may thus, serve as a platform for new initiatives in the field. The book reviews the research into the pharmacological mechanisms involved, the classes of drugs in development and the clinical trialsmethodology. The editors have gathered together the leading international experts to produce a book that will appeal neurologists caring for headache patients, researchers in the field and those based in the pharmaceutical industry.
Product Details
OUP Oxford
83758
9780198528449
9780198528449

Data sheet

Publication date
2004
Issue number
1
Cover
hard cover
Pages count
292
Dimensions (mm)
174 x 249
Weight (g)
600
  • Section I - Methodology of prophylactic trials; Principles of preventive pharmacotherapy in primary headache; Methodology and implementation of systematic reviews; Adverse events, equally important as efficacy as an outcome parameter?; Methodology of prophylactic trials: discussion summary; Section II - Prophylactic drugs I; Key issues in the methodology of prophylactic migraine trials; Migraine prophylaxis: a pharmacoepidemiological study of practices used by general practitioners and neurologists in France; Preventive treatment of migraine headache with rofecoxib; Prophylactic treatment and course of the disease in headache associated with sexual activity; Propylactic drugs I: discussion summary; Section III - Prophylactic drugs II; Prevention of migraine: betablockers and amine agonists: efficacy; Antiepileptic drugs in migraine prevention; Mechanism(s) of action of the antiepileptic drugs Valproic Acid, Gabapentin, and Topiramate: implications for the prophylactic management of migraine; Experience with topiramate in patients with refractory migraine; Topiramate in a selective group of therapy refractory headache patients; Prophylactic drugs II: discussion summary; Section IV - Prophylactic Drugs III; Efficacy of antidepressants in headache prophylaxis; Antidepressants: mechanisms of action; Other prophylactic anti-migraine agents: riboflavin feverfew, magnesium, botulinum toxin and calcium antagonists; Treatment of chronic tension type headache with mirtazapine; Botulinum toxin type A in the treatment of refractory headache; Botulinum toxin A in the prophylaxis of migraine - a double-blind, placebo-controlled, randomised study comparing frontal and cervical injection; Description of a prospective, multicenter observational study of headache treatment with Botulinum toxin type A: the program to assess treatment strategies (PATS) registry; Mechanisms of the antinociceptive effect of subcutaneous BOTOX: inhibition of peripheral and central nociceptive processing; Survey on expenditure for analgesics in chronic tension headache and its changes following botulinum toxin type A preventive treatment; Prophylactic treatment of migraine with lomerizine hydrochloride; Prophylactic drugs III: discussion summary; Section V - New Targets I; Antagonising peripheral sensitisation in migraine; New possibilities for antimigraine therapy via 5-HT receptors?; Dihydroergotamine interaction with 5-HT2 receptors and its relevance to migraine; Migraine prophylaxis with drugs influencing the angiotensin system; Naratriptan in the preventive treatment of refractory chronic migraine; PROMISE study (PROphylaxis of MIgraine with SEglor); Serotinin receptors and migraine prophylaxis - the case of dihydroergotamine; What is the mechanism of action of ACE inhibitors in migraine prophylaxis?; Triptans with methysergide; New Targets I: discussion summary; Section VI - new targets II; Nitric oxide and its signalling pathways: a rich source of potential targets for migraine therapy; Calcitonin gene related peptide and migraine; Phosphodiesterases, cyclic nucleotides, and their role in migraine; The prostaglandin-E1-analog misoprostol in the prophylactic treatment of refractory cluster headache and trigeminal neuralgia; New targets II: discussion summary;
Comments (0)

  • Frequently purchased together

    No products available